Promega

The test uses multiplex PCR fragment analysis with Promega-designed five-mononucleotide repeat markers to detect the MSI-high phenotype within tumor tissues.

The two companies have signed a collaboration agreement to provide Promega's microsatellite instability testing technology for immuno-oncology.

Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.

The test, which is currently for research use only, uses fluorescent multiplex PCR to co-amplify seven markers for analysis of the MSI-high phenotype.